The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status. OBJECTIVE: To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites. INTERVENTIONS: The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days. MAIN OUTCOMES AND MEASURES: The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events. RESULTS: Among the 300 patients who were randomized (median age, 61 years [interquartile range {IQR}, 52-68 years]; 64 [21%] women; 178 [59%] with type 2 diabetes; median LVEF of 25% [IQR, 19%-33%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31). There were no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0.89-1.88]; P = .17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and hypoglycemic events were infrequent (2 [1%] vs 4 [3%], respectively). CONCLUSIONS AND RELEVANCE: Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01800968.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in earlier smaller studies with liraglutide in patients with HF with reduced left ventricular ejection fraction, the GLP-1RA was associated with increased incidence of serious cardiac events (rhythm disorders, worsening of HF)”
From Safety of Semaglutide (2021) · cites this paper as [102]
Experimental — accuracy not yet measuredIn the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Furthermore, 2 small randomized clinical trials of liraglutide in patients with HF with reduced EF, 1 of which enrolled patients with recent HF hospitalization, suggested potential harm of liraglutide, although neither trial found statistically significant differences.36,37”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [36]
In the citing paper
“In a placebo-controlled FIGHT trial, of patients with HFrEF, with and without T2DM (41%), liraglutide was not associated with an improvement in the composite primary endpoint of death, rehospitalization and NT-proBNP change.181”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,651
Anand, I. S., Fisher, L. D., Chiang, Y., Latini, R., Masson, S., Maggioni, A. P., Glazer, R. D., Tognoni, G., & Cohn, J. N. (2003) · Circulation · doi:10.1161/01.cir.0000054164.99881.00 · Cited by 857
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 706
Kumarathurai, P., Sajadieh, A., Anholm, C., Kristiansen, O. P., Haugaard, S. B., & Nielsen, O. W. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01205-2 · Cited by 31
Singh, A. K., & Singh, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1588110 · Cited by 31
Bonaventura, A., Carbone, S., Dixon, D. L., Abbate, A., & Montecucco, F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12890 · Cited by 32
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 30
Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction
van Essen, B. J., Ceelen, D. C. H., Ouwerkerk, W., Teng, T. K., Tharshana, G. N., Hew, F. M., Butler, J., Zannad, F. M., Lam, C. S. P., Ezekowitz, J. A., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.054 · Cited by 35
Owens, D. R., Monnier, L., & Hanefeld, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12998 · Cited by 29
Tanaka, A., & Node, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0731-y · Cited by 31
Katsurada, K., Nandi, S. S., Zheng, H., Liu, X., Sharma, N. M., & Patel, K. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01029-0 · Cited by 31
Nielsen, R. R., Jorsal, A., Tougaard, R. S., Rasmussen, J., Schou, M., Videbæk, L. M., Gustafsson, I., Faber, J. O., Flyvbjerg, A., Wiggers, H., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14135 · Cited by 30
Range of adiposity and cardiorenal syndrome
Pazos, F. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i8.322 · Cited by 32
Ferreira, J. P., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D. M., Packer, M., Zannad, F. M., Leite-Moreira, A. F., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2660 · Cited by 32
Yang, D.-Y. D., He, X., Liang, H., Zhang, S., Zhong, X., Luo, C., Du, Z., He, J., Zhuang, X., & Liao, X. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0853-x · Cited by 29
The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure
Rodolico, D., Schiattarella, G. G., & Taegtmeyer, H. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.02.007 · Cited by 30
Parab, P. T., Chaudhary, P., Mukhtar, S., Moradi, A., Kodali, A., Okoye, C., Klein, D., Mohamoud, I., Olanisa, O. O., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.45487 · Cited by 31
Standardized Definitions of Changes in Kidney Function in Trials of Heart Failure
Lala, A., Coca, S. G., Feinman, J., HAMO, C. E., Fiuzat, M., Abraham, W. T., O’Connor, C. M., Lindenfeld, J., Januzzi, J. L., Cavagna, I., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.041 · Cited by 31
Cardiac structure and function before and after bariatric surgery: a clinical overview
Lascaris, B., Pouwels, S., Houthuizen, P., Dekker, L., Nienhuijs, S. W., Bouwman, R. A., & Buise, M. P. (2018) · Clinical Obesity · doi:10.1111/cob.12278 · Cited by 29
Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
Longo, M., Scappaticcio, L., Cirillo, P., Maio, A., Carotenuto, R. M., Maiorino, M. I., Bellastella, G., & Esposito, K. (2022) · Biomolecules · doi:10.3390/biom12020272 · Cited by 30
Molecular Epidemiology of Heart Failure
Smith, J. G. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.010 · Cited by 30
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 37
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 36
Repetitive levosimendan treatment in the management of advanced heart failure
Oliva, F. G., Colet, J. C., Fedele, F., Fruhwald, F. M., Gustafsson, F., Kivikko, M., Borbély, A., Pölzl, G., & Tschöpe, C. (2018) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy040 · Cited by 28
New drugs in preclinical and early stage clinical development in the treatment of heart failure
Tamargo, J. L., Caballero, R., & Delpón, E. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1551357 · Cited by 28
Liraglutide relieves cardiac dilated function than DPP ‐4 inhibitors
Hiramatsu, T., Asano, Y., Mabuchi, M., Imai, K., Iguchi, D., & Furuta, S. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13007 · Cited by 28
Mosenzon, O., Bain, S. C., Heerspink, H. J. L., Idorn, T., Mann, J. F. E., Persson, F., Pratley, R. E., Rasmussen, S., Rossing, P. R., von Scholten, B. J., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14126 · Cited by 26
Avogaro, A., Azzolina, D., Gregori, D., de Kreutzenberg, S., Fadini, G. P., & Mannucci, E. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.03.032 · Cited by 27
Chen, W. J. Y., Diamant, M., de Boer, K., Harms, H. J., Robbers, L. F. H. J., van Rossum, A. C., Kramer, M. H. H., Lammertsma, A. A., & Knaapen, P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0549-z · Cited by 27
Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
Shin, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1171-0 · Cited by 27
Wong, S. Y., Lee, A. R. Y. B., Sia, A. H. J., Wo, Y. J., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Ong, C. C., Teo, L., Yeo, T., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07360-w · Cited by 26
Battistoni, A., Piras, L., Tartaglia, N., Carrano, F. M., Vitis, C. D., & Barbato, E. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1669685 · Cited by 31
Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus
Trang, A., & Aguilar, D. A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0371-7 · Cited by 26
Congestive heart failure caused by silent ischemia and silent myocardial infarction
Valensi, P. E., & Meune, C. (2019) · Herz · doi:10.1007/s00059-019-4798-3 · Cited by 32
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
King, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 28
Pölzl, G., Altenberger, J., Colet, J. C., Delgado, J. F., Fedele, F., García‐González, M. J., Gustafsson, F., Masip, J., Papp, Z., Störk, S., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3006 · Cited by 26
Villaschi, A., Ferrante, G., Cannata, F., Pini, D., Pagnesi, M., Corrada, E., Reimers, B., Mehran, R., Federici, M., Savarese, G., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02362-6 · Cited by 26
Nyström, T., Santos‐Pardo, I., Hedberg, F., Wardell, J., Witt, N., Cao, Y., Bojö, L., Nilsson, B., & JENDLE, J. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00325 · Cited by 25
Effects of sodium glucose cotransporter type 2 inhibitors on heart failure
Nassif, M. E., & Kosiborod, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13678 · Cited by 26
Cardiovascular Risks and Benefits of Medications Used for Weight Loss
Bramante, C. T., Raatz, S. J., Bomberg, E. M., Bensignor, M. O., & Ryder, J. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00883 · Cited by 27
Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway
Ni, X., Feng, X., Wang, Z., Zhang, Y., Little, P. J., Cao, Y., Xu, S., Tang, L., & Weng, J. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01265-0 · Cited by 27
GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Chen, T., Hu, E.-H., Chen, D., Lin, Y., Chou, T., Lin, M., Yang, N., Wang, C., Hung, M., & Tsai, M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.30952 · Cited by 28
Yeong, T. J. J., Mai, A. S., Lim, O. Z.-H., Ng, C. H., Chin, Y. H., Tay, P. W. L., Lin, C., Muthiah, M. D., Khoo, C. M., Dalakoti, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13822 · Cited by 25
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258401 · Cited by 27
Effects of liraglutide on hemodynamic parameters in patients with heart failure
Zhang, J. Y., Wang, X. Y., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18570 · Cited by 26
Wägner, A. M., Miranda-Calderín, G., Ugarte-Lopetegui, M. A., Marrero-Santiago, H., Suárez-Castellano, L., López-Madrazo, M. J., Alberiche-Ruano, M. P., Ahmed, N. A., Alemán, C., Castellot-Martín, A., et al. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.010 · Cited by 25
Strategies of Unloading the Failing Heart from Metabolic Stress
Koutroumpakis, E., Jozwik, B., Aguilar, D. A., & Taegtmeyer, H. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.035 · Cited by 26
Shiraki, A., Oyama, J., Nishikido, T., & Node, K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0966-2 · Cited by 24
Hafkamp, F. J., Tio, R. A., Otterspoor, L., Greef, T. V.-D., van Steenbergen, G. J., van de Ven, A. R. T., Smits, G., Post, H., & van Veghel, D. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10212-8 · Cited by 24
Chi, M., Nie, Y., Su, Y., Wang, N., Li, A., Ma, T., & Hou, Y. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad284 · Cited by 24
Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus
Ikeda, M., & Shimazawa, R. (2019) · Journal of General and Family Medicine · doi:10.1002/jgf2.244 · Cited by 24
Sabouret, P. F., Galati, G., Angoulvant, D., Андреевна, Г. О., Castelletti, S., Pathak, A., Metra, M., & Margonato, A. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa051 · Cited by 24
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 25
Singh, V., Sun, J. M., Cheng, S. C., Kwan, A. C., & Velazquez, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03352-y · Cited by 31
Pharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 23
Rai, A. K., Lee, B., Gomez, R., Rajendran, D., Khan, M., & Garikipati, V. N. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.612722 · Cited by 23
Durak, A. T., Akkuş, E., Canpolat, A. G., Tuncay, E., Çorapçıoğlu, D., & Turan, B. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13590 · Cited by 22
Merza, N., Akram, M., Mengal, A., Rashid, A. M., Mahboob, A., Faryad, M., Fatima, Z., Ahmed, M., & Ansari, S. A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101602 · Cited by 24
Glucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure
Melenovský, V., Beneš, J., Franeková, J., Kovář, J., Borlaug, B. A., Segeťová, M., Tura, A., & Pelikánová, T. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005290 · Cited by 23
Zhao, H., Liu, Y., Liu, M., Xu, Y., Ling, Q., Lin, W., Zhang, J., Yan, Z., Ma, J., Li, W., et al. (2023) · Drugs · doi:10.1007/s40265-023-01932-2 · Cited by 24
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 29
Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
Thompson, P. L., & Davis, T. M. E. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.10.008 · Cited by 23
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Tadić, M., Sala, C., Saeed, S., Grassi, G. M., Mancia, G., Rottbauer, W., & Cuspidi, C. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10106-9 · Cited by 23
Gallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 23
Singh, A. K., & Singh, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1287562 · Cited by 21
Lopez, P. D., Bhatia, K., Bohra, C., Mahmood, K., Baruch, L., & Eng, C. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.07.012 · Cited by 24
Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 26
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 21
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 23
Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
Bistola, V., Lambadiari, V., Dimitriadis, G., Ioannidis, I., Makrilakis, K., Tentolouris, N., Τσάπας, Α., & Parissis, J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9674-3 · Cited by 21
Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism
Karlstaedt, A., Schiffer, W. B., & Taegtmeyer, H. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00071 · Cited by 21
Suhrs, H. E., Raft, K. F., Bove, K. B., Madsbad, S., Holst, J. J., Zander, M., & Prescott, E. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.12.005 · Cited by 21
Nassif, M. E., & Kosiborod, M. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.025 · Cited by 20
Ferrini, M., Johansson, I., & Aboyans, V. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885461 · Cited by 21
Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., Ishii, H., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0865 · Cited by 24
Siddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 24
Marques, P. S., Travlos, C. K., Matias, P., Neves, J. S., Tsoukas, M. A., Mavrakanas, T. A., Joza, J. E., Ferreira, J. P., & Sharma, A. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102573 · Cited by 21
Endpoints in Heart Failure Drug Development
Hussain, A., Misra, A., & Bozkurt, B. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.13 · Cited by 21
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment
Madonna, R., Biondi, F., Ghelardoni, S., D'Alleva, A., Quarta, S., & Massaro, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.030 · Cited by 20
Reddy, Y. N. V., Borlaug, B. A., O’Connor, C. M., & Gersh, B. J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz364 · Cited by 22
How Diabetes and Heart Failure Modulate Each Other and Condition Management
Randhawa, V. K., Dhanvantari, S., & Connelly, K. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.11.014 · Cited by 20
Composite End Points in Clinical Trials of Heart Failure Therapy
Brown, P. M., & Ezekowitz, J. A. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003222 · Cited by 20
Packer, M. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1047 · Cited by 20
Nesti, L., & Tricò, D. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.818 · Cited by 19
Diabetic cardiomyopathy revisited: The interplay between diabetes and heart failure
Mann, C., Braunwald, E., & Zelniker, T. A. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133554 · Cited by 23
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Hu, Y., Zhao, Y., Dai, N., Zhou, Y., Yao, Y., Li, Z., Cai, W., Xiong, W., Song, S., Deng, X., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1066 · Cited by 20
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Lo, C. W. H., Fei, Y., & Cheung, B. M. Y. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.19 · Cited by 20
Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway
Arad, M., Waldman, M., Abraham, N. G., & Hochhauser, E. (2020) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2020.106454 · Cited by 20
Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
Liang, B., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01088-3 · Cited by 19
Cohen, J. B., Hanff, T. C., Corrales‐Medina, V., William, P., Renna, N. F., Rosado‐Santander, N. R., Mori, J. E. R., Spaak, J., Andrade-Villanueva, J. F., Chang, T. I., et al. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14011 · Cited by 19
Diabetes Management in Patients with Heart Failure
Shen, J., & Greenberg, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0296 · Cited by 21
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Diabetology International · doi:10.1007/s13340-022-00605-x · Cited by 20
Jorsal, A., Wiggers, H., & McMurray, J. J. V. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.007 · Cited by 20
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 19
Zaher, W., Rocca, D. G. D., Pannone, L., Bovéda, S., de Asmundis, C., Chierchia, G., & Sorgente, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051316 · Cited by 18
Yagi, K., Imamura, T., Tada, H., Chujo, D., Liu, J., Shima, Y., Ohbatake, A., Miyamoto, Y., Okazaki, S., Ito, N., et al. (2021) · Journal of Diabetes Research · doi:10.1155/2021/8838026 · Cited by 18
Chirinos, J. A., López-Jaramillo, P. A., Giamarellos‐Bourboulis, E. J., Dávila-Del-Carpio, G., Bizri, A. R., Andrade-Villanueva, J. F., Salman, O., Cure-Cure, C., Rosado‐Santander, N. R., Giraldo, M. P. C., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00698-3 · Cited by 18
Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
Oduah, M.-T. A., Sundaram, V., & Reddy, Y. N. V. (2023) · Cardiac failure review · doi:10.15420/cfr.2022.25 · Cited by 18
Wallner, M., Biber, M. E., Stolfo, D., Sinagra, G., Benson, L., Dahlström, U., Guðbjörnsdóttir, S., Cosentino, F., Mol, P. G. M., Rosano, G. M. C., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae026 · Cited by 21
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14202 · Cited by 21
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00723-8 · Cited by 19
Metadata
- Authors
- Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., McNulty, S. E., Anstrom, K. J., Shah, M. R., Braunwald, E., Cappola, T. P., & for the NHLBI Heart Failure Clinical Research Network
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- Mayo Clinic (US)
- Brigham and Women's Hospital (US)
- University Hospitals of Cleveland (US)
- Emory University (US)
- Washington University in St. Louis (US)
- Thomas Jefferson University (US)
- Tufts University (US)
- National Heart, Lung, and Blood Institute (US)
- Brigham and Women’s Hospital, Boston, Massachusetts
- Corresponding author
- Margulies, Kenneth B.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-08-02
- Volume
- 316
- Issue
- 5
- Pages
- 500
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5021525
- OpenAlex
- W2505843168
- Cited by
- 706
- References
- 24
- Citations by year
- 2026: 85 · 2025: 99 · 2024: 75 · 2023: 58 · 2022: 46 · 2021: 50 · 2020: 77 · 2019: 68 · 2018: 78 · 2017: 56 · 2016: 13
- FWCI
- 59.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U10HL110297, U10HL110342, U10HL084904, U10HL110262, U01HL084861, U10HL110309, U10HL110336, U10HL110302, U10HL110337, U10HL110312, U10HL110338)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- liraglutide, GLP-1 receptor agonists, advanced heart failure, reduced left ventricular ejection fraction, clinical stability, heart failure readmission, mortality, NT-proBNP, myocardial metabolism, type 2 diabetes, cardiac structure and function, 6-minute walk distance, quality of life, subcutaneous injection, cardioprotection
- MeSH terms
- Liraglutide, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Middle Aged, Patient Readmission, Quality of Life, Stroke Volume, United States, Odds Ratio, Treatment Outcome, Ventricular Dysfunction, Left, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
